{
    "root": "db9c7b16-d22e-472c-928b-8cc426573714",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "TEPYLUTE",
    "value": "20250204",
    "ingredients": [
        {
            "name": "THIOTEPA",
            "code": "905Z5W3GKH"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        }
    ],
    "indications": "tepylute alkylating indicated treatment adenocarcinoma breast ovary . ( 1.1 )",
    "contraindications": "recommended dose tepylute treatment adenocarcinoma breast ovary 0.3 mg/kg 0.4 mg/kg intravenously . ( 2.1 ) full prescribing information preparation instructions . ( 2.2 )",
    "warningsAndPrecautions": "supplied tepylute injection supplied clear , colorless almost colorless solution . vial stopper made natural rubber latex . tepylute injection ndc number strength vial presentation 81927-105-01 15 mg/ 1.5 ml ( 10 mg/ml ) single-dose vial , carton 1 81927-106-01 100 mg/ 10 ml ( 10 mg/ml ) multiple-dose vial , carton 1",
    "adverseReactions": "tepylute contraindicated : patients severe hypersensitivity thiotepa [ ( 5.2 ) ] concomitant live attenuated vaccines [ ( 5.4 ) ]",
    "indications_original": "TEPYLUTE is an alkylating drug indicated for treatment of adenocarcinoma of the breast or ovary. ( 1.1 )",
    "contraindications_original": "The recommended dose of TEPYLUTE for treatment of adenocarcinoma of the breast or ovary is 0.3 mg/kg to 0.4 mg/kg intravenously. ( 2.1 ) See full prescribing information for preparation instructions. ( 2.2 )",
    "warningsAndPrecautions_original": "How Supplied\n                        \n                        TEPYLUTE injection is supplied as a clear, colorless or almost colorless solution. The vial stopper is not made with natural rubber latex.\n                        TEPYLUTE Injection\n                        \n                           \n                           \n                              \n                                 \n                                    \u00a0NDC Number\n                                 \n                                 \n                                    \u00a0Strength\n                                 \n                                 \n                                    \u00a0Vial Presentation\n                                 \n                              \n                              \n                                 \u00a081927-105-01\n                                 \u00a015 mg/ 1.5 mL\u00a0(10 mg/mL)\n                                 \u00a0Single-dose vial, carton of 1\n                              \n                              \n                                 \u00a081927-106-01\n                                 \u00a0100 mg/ 10 mL\u00a0(10 mg/mL)\n                                 \u00a0Multiple-dose vial, carton of 1",
    "adverseReactions_original": "TEPYLUTE is contraindicated in:\n                  \n                     Patients with severe hypersensitivity to thiotepa [see Warnings and Precautions (5.2)]\n                     \n                     Concomitant use with live or attenuated vaccines [see Warnings and Precautions (5.4)]"
}